MetaCap

Capricor Therapeutics (CAPR) vs Prothena (PRTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed Prothena (PRTA) over the past year, gaining 32.0% versus a loss of 21.6%. Over five years, CAPR leads with a +122.6% price change compared with -83.3% for PRTA. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $422.1 million), about 1.0 times the size, while Prothena is growing revenue faster (-92.8% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%PRTA-21.56%
+542%+241%-60%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%PRTA-86.00%
+1012%+433%-145%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus PRTA key metrics
MetricCAPRPRTA
Share price$7.59$8.22
Market cap$441.30M$422.10M
1-day change+0.80%-2.14%
YTD return-73.70%-13.93%
1-year return+32.00%-21.56%
5-year return+122.58%-83.28%
EPS (TTM)$-2.65$-0.45
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$9.68M
Revenue growth (YoY)-100.00%-92.83%
Net income (latest FY)$-105.04M$-244.09M
Operating margin—-2216.44%
Net margin—-2520.57%
52-week high$40.37$11.80
52-week low$2.96$7.70
Distance from 52-week high-81.20%-30.34%
Analyst consensusbuybuy
Avg. price target upside+259.03%+160.34%
Average volume4.73M487.91K
Shares outstanding58.14M51.35M
Employees23167
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed PRTA by 53.6 percentage points over the past year.
  • Prothena grew revenue faster in its latest fiscal year (-92.83% vs -100.00%).

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About Prothena

PRTA stock →

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.

Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees

CAPR vs PRTA FAQ

Which is bigger, Capricor Therapeutics or Prothena?

Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $422.10M for Prothena (PRTA).

Which stock has performed better over the past year, CAPR or PRTA?

CAPR returned +32.00% over the past 12 months, compared with -21.56% for PRTA (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and Prothena in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons